



05-21-09

1642

Docket No.: PF-0229-1 DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: NOVEL HUMAN MITOCHONDRIAL MEMBRANE PROTEIN

Serial No.: 09/208,619

Filing Date: December 08, 1998

Group Art Unit: 1642

Commissioner for Patents
USPTO
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 26 2004

TECH CENTER 1600/2800

CERTIFICATE UNDER 37 C.F.R. § 3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8951, Frame 0923, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. **22428** as attorneys/agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

✓ Please direct all correspondence to:

Michele M. Simkin, Esq.
Reg. No. 34,717
Customer No.: **22428**
Foley & Lardner LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone: Tel: (202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine of imprisonment, or both, under Section 1001, Title 18, of the United States Code, and that such willful false statements may jeopardize the validity of the patent.


INCYTE CORPORATION

Date:

April 28, 2004

By:

Patricia Anne Schreck
Patricia Anne Schreck
Executive VP, General Counsel



05-21-04

1642

Certificate of Mailing

"Express Mail" mailing label number EV 332011039 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on May 20, 2004.

By: _____

Printed: Jeannie G. Labra

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Transmitted herewith are the following:

1. CERTIFICATES UNDER 37 C.F.R. § 3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS (140 pp.); and
2. Copy of Limited Recognition - 37 C.F.R. 10.9(b) (1 pp.).

A duplicate copy of this sheet is enclosed.


Respectfully submitted,
INCYTE CORPORATION

Date: _____

May 20, 2004

Sharmila M. Pandharipande
Limited Recognition (37 C.F.R. § 10.9(b)) attached
Direct Dial Telephone: (650) 843-7469

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Sharmila Pandharipande is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Incyte Genomics to prepare and prosecute patent applications wherein Incyte Genomics is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Sharmila Pandharipande ceases to lawfully reside in the United States, (ii) Sharmila Pandharipande's employment with Incyte Genomics ceases or is terminated, or (iii) Sharmila Pandharipande ceases to remain or reside in the United States on an H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: February 17, 2005



Harry I. Moatz
Director of Enrollment and Discipline